Syntara Announces Positive Results from SNT-4728 iRBD Phase 2 Trial
Key points
- Significant reduction in brain inflammation observed in Phase 2 trial
- Improvement in motor function 12 weeks after treatment cessation
- Positive safety profile with no serious adverse events reported
Full summary
Syntara Limited, a clinical-stage drug development company, announced further significant results from its Phase 2 study of SNT-4728 in participants with isolated REM Sleep Behaviour Disorder (iRBD). The study demonstrated a statistically significant reduction in brain inflammation and improvement in motor function, supporting SNT-4728's potential as a disease-modifying therapy in prodromal and early Parkinson's Disease. The trial showed a statistically significant reduction in brain inflammation in the putamen and a significant difference in clinician-assessed motor signs at Week 24. SNT-4728 also demonstrated a favorable safety and tolerability profile with no treatment-related serious adverse events reported.
Outlook
Syntara plans to present these findings to the Parkinson's community and complete further analysis from this study.
Summary generated by a large language model. Please interpret with care.